Poland· PL-100530270
Ryaltris
A mometason, kombinationen product containing mometasoni furoas + olopatadinum, registered in Poland by InPharm Sp. z o.o.. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Mometason, kombinationen is registered in 10 of 19 countries.
Countries holding a registration under ATC R01AD59 (mometason, kombinationen), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Mometason, kombinationen · ATC R01AD59
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Mometasoni furoas + Olopatadinum
- Manufacturer
- InPharm Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- R01AD59
- ATC class
- Mometason, Kombinationen
- Defined daily dose
- 0.2 mg, N
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991590154
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mometason, kombinationen in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsRyaltris 25/600 microgram/dosis neusspray, suspensieMedcor Pharmaceuticals B.V.
- CzechiaRYALTRISGlenmark Pharmaceuticals s.r.o., Praha
- SwitzerlandRyaltris 25 μg / 600 μg, Nasenspray, SuspensionNOBEL Pharma Schweiz AG
- United StatesRyaltrisGlenmark Pharmaceuticals Inc., USA
- SwedenMometasone furoate/Olopatadine Glenmark 25 mikrogram/dos + 600 mikrogram/dos Nässpray, suspensionGlenmark Arzneimittel GmbH
- United KingdomRyaltris 25micrograms/dose / 600micrograms/dose nasal sprayNecessity Supplies Ltd
- IrelandRyaltris 25 microgram/actuation + 600 microgram/actuation nasal spray, suspensionGlenmark Pharmaceuticals s.r.o.
- GermanyRyaltrisGlenmark Pharmaceuticals S.R.O.
Authorised across Europe · EMA
The same active substance is authorised in 20 EEA countries. Names it is sold under:
- Austria · Ryaltris
- Belgium · Ryaltris
- Czechia · Ryaltris
- Germany · Ryaltris
- Denmark · Ryaltris
- Spain · Ryaltris
- Finland · Ryaltris
- France · Ryaltris
- United Kingdom (Northern Ireland) · Ryaltris
- Ireland · Ryaltris
- Italy · Rineffix, Ryaltris
- Lithuania · Ryaltris
- Luxembourg · Ryaltris
- Latvia · Ryaltris
- Malta · Ryaltris
- Netherlands · Ryaltris
- Norway · Ryaltris
- Romania · Ryaltris
- Sweden · Mometasone Furoate/Olopatadine Glenmark, Ryaltris
- Slovakia · Ryaltris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/141eeea3-119a-4a8a-80b2-874ed5dbc28c GET /v1/drugs/141eeea3-119a-4a8a-80b2-874ed5dbc28c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Aerozol do nosa, zawiesina",
"source": "urpl",
"strength": "25 mcg/dawkę + 600 mcg/dawkę",
"packaging": "05909991590154 ¦ Rp ¦ 165042\n1 butelka 240 dawek (30 ml)",
"substance": "Mometasoni furoas 25 mcg/dawkę + Olopatadinum 600 mcg/dawkę",
"common_name": "Mometasoni furoas + Olopatadinum",
"pl_product_id": "100530270",
"pozwolenie_nr": "390/25",
"auth_procedure": "IR",
"authorisation_validity": "2030-12-12"
}See everything about mometason, kombinationen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.